1,879 results match your criteria Journal of Drug Targeting [Journal]


Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery.

J Drug Target 2019 Feb 12:1-21. Epub 2019 Feb 12.

a Department of Pharmaceutics , Utrecht Institute for Pharmaceutical Sciences, Utrecht University , universiteitsweg 99, 3584 CG , Utrecht , The Netherlands.

Asymmetrical lipid nanoparticles are interesting nanocarriers for charged molecules, like nucleic acids. They promise control over inner and outer charge. High charge density on the inside is favorable for efficient condensation and charge neutralization of highly charged biopharmaceuticals, while a neutral or slightly negative outer layer promotes biocompatibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1579819DOI Listing
February 2019

Efficacy of intravesical targeting of novel quorum sensing inhibitor nanoparticles against Pseudomonas aeruginosa biofilm-associated murine pyelonephritis.

J Drug Target 2019 Feb 11:1-9. Epub 2019 Feb 11.

a Department of Microbiology , Panjab University , Chandigarh , India.

Pseudomonas aeruginosa biofilm-associated pyelonephritis is a severe infection that can lead to mortality. There are no strategies that can effectively manage this infection since the pathogenesis is controlled by quorum sensing (QS) regulated virulence and recalcitrant biofilms. QS inhibitors (QSIs) are emerging therapeutics against such infections but are associated with cytotoxicity or low bioactivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1574802DOI Listing
February 2019

A Tribute to Professor Patrick Couvreur: A Creative and Visionary Scientist in the field of Nanomedicine.

Authors:
Elias Fattal

J Drug Target 2019 Feb 7:1-2. Epub 2019 Feb 7.

a University of Paris Sud, Institut Galien Paris-Sud , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1579821DOI Listing
February 2019
8 Reads

Mycobacterium tuberculosis metC (Rv3340) derived hydrogen sulfide conferring bacteria stress survival.

J Drug Target 2019 Feb 7:1-35. Epub 2019 Feb 7.

a Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Ministry of Education, School of Life Sciences, Southwest University , Chongqing 400715 , China.

Tuberculosis, especially multidrug resistant cases, remains an enormous public health threat. Mycobacterium tuberculosis metC (Rv3340) an enzyme involved in methionine biosynthesis was identified and characterized for antimicrobial susceptibility. We reported that the overexpression of Rv3340 in Mycobacterium smegmatis (Ms_Rv3340) produces hydrogen sulfide (HS) for its energy in harsh conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1579820DOI Listing
February 2019

From Poly(Alkyl Cyanoacrylate) to Squalene as Core Material to Design Nanomedicines.

J Drug Target 2019 Feb 5:1-54. Epub 2019 Feb 5.

a Institut Galien Paris-Sud, UMR 8612, CNRS, Univ. Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie , 5 rue JB Clément , 92296 Châtenay-Malabry , France.

The present review article covers the most important steps of the pioneering work of Patrick Couvreur and tries to shed light on his outstanding career that has been a source of inspiration for many decades. His discovery of the biodegradable poly(alkyl cyanoacrylate) (PACA) nanoparticles has opened large perspectives in nanomedicine. Indeed, nanoparticles made from different types of PACA monomers have been used in different applications such as the treatment of intracellular infections or the treatment of multidrug resistant hepatocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1579822DOI Listing
February 2019
11 Reads

Correction.

Authors:

J Drug Target 2019 Jan 31. Epub 2019 Jan 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1577538DOI Listing
January 2019

Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease.

J Drug Target 2019 Jan 29:1-11. Epub 2019 Jan 29.

c Department of Pharmacy , University of Salerno , Fisciano (SA) , Italy.

Neuroinflammation occurs in the early stages of Alzheimer's disease (AD). Thus, anti-inflammatory drugs in this asymptomatic initial phase could slow down AD progression, provided they enter the brain. Direct nose-to-brain drug transport occurs along olfactory or trigeminal nerves, bypassing the blood-brain barrier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1574300DOI Listing
January 2019
2 Reads

Advances in curcumin-loaded nanopreparations: improving bioavailability and overcoming inherent drawbacks.

J Drug Target 2019 Jan 23:1-32. Epub 2019 Jan 23.

a College of Pharmacy , Shandong University , Jinan , China.

Curcumin (CUR), one of the major extracts of turmeric, has gained extensive attention owing to its extraordinary benefits as anti-cancer, anti-bacterial, anti-ulcerative, anti-depressant, anti-inflammatory and wound healing agent. However, a major barrier in its application lies in its inherent nature of low water solubility, instability, and short half-life. Different strategies have been adopted to overcome these barriers like preparing nano-sized formulations and exploiting stable and hydrophilic derivatives, and collaborative drug delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1572158DOI Listing
January 2019
2 Reads

Low-intensity light-induced paclitaxel release from lipid-based nano-delivery systems.

J Drug Target 2019 Jan 19:1-13. Epub 2019 Jan 19.

a Department of Pharmacy Sciences , Creighton University , Omaha , NE , USA.

Light-induced drug release has been explored as a strategy for externally modulating the release of drug from delivery systems. This study reports the development of a solid lipid nanoparticulate system (SLN) for paclitaxel (PTX), where photosensitizer-mediated oxidation of lipids was used as a mechanism for controlling the drug release. Low-intensity (23 mW/cm) near-infrared (around 730 nm) illumination was externally applied as the light source. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1571066DOI Listing
January 2019
2 Reads

MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation.

J Drug Target 2019 Jan 18:1-10. Epub 2019 Jan 18.

a Center for Pharmaceutical Biotechnology and Nanomedicine Northeastern University , Boston , MA , USA.

p53, The tumour suppressor protein encoded by P53 gene, is the most commonly altered protein in the human malignancies. MDM2 controls the p53 activity through an autoregulatory feedback loop. p53 activates the expression of MDM2 and in return, MDM2 blocks the p53 activity through various mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1570518DOI Listing
January 2019
1 Read

Paclitaxel-loaded multifunctional nanoparticles for the targeted treatment of glioblastoma.

J Drug Target 2019 Jan 11:1-10. Epub 2019 Jan 11.

a Université Catholique de Louvain, Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute ,   Brussels , Belgium.

Introduction: We hypothesised that the active targeting of αvβ3 integrin overexpressed in neoangiogenic blood vessels and glioblastoma (GBM) cells combined with magnetic targeting of paclitaxel- and SPIO-loaded PLGA-based nanoparticles could improve accumulation of nanoparticles in the tumour and therefore improve the treatment of GBM.

Methods: PTX/SPIO PLGA nanoparticles with or without RGD-grafting were characterised. Their in vitro cellular uptake and cytotoxicity was evaluated by fluorospectroscopy and MTT assay. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2019.1567738DOI Listing
January 2019
6 Reads

A mitochondrion-targeting tanshinone IIA derivative attenuates myocardial hypoxia reoxygenation injury through a SDH-dependent antioxidant mechanism.

J Drug Target 2019 Jan 11:1-7. Epub 2019 Jan 11.

a State Key Laboratory of Natural Medicines , China Pharmaceutical University , Nanjing , Jiangsu , P. R. China.

The medicinal values of many natural bioactive components to treat myocardial ischaemia reperfusion (I/R) injury are limited by their poor permeability. Herein, we demonstrate that an original tanshinone IIA derivative (Tan-TPP) could probably be improved myocardial I/R injury suppressant. It was optimised by mitochondria targeting group triphenylphosphine (TPP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1566338DOI Listing
January 2019
1 Read

Construction of novel procoagulant protein targeting neuropilin-1 on tumour vasculature for tumour embolization therapy.

J Drug Target 2019 Jan 21:1-11. Epub 2019 Jan 21.

a Cancer Research Center, Medical College , Xiamen University , Xiamen , China.

The cellular transmembrane receptor Neuropilin-1(NRP-1) is overexpressed in tumour tissue and endothelial cells of tumour vessels, whereas it has limited expression in normal tissues. This study aimed to design a novel recombinant protein tTF-EG3287, which consisting of the truncated tissue factor (tTF) and the NRP-1 targeting peptide EG3287. The procoagulant protein selectively activates blood coagulation in tumour vessels once bound to the cell surface of the tumour vasculature by a targeting peptide EG3287. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2019.1566337DOI Listing
January 2019
10 Reads

Design, stability and efficacy of a new targeting peptide for nanoparticulate drug delivery to SH-SY5Y neuroblastoma cells.

J Drug Target 2019 Jan 9:1-12. Epub 2019 Jan 9.

a School of Pharmacy & Pharmaceutical Sciences , Ulster University , Coleraine , UK.

In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific neural cell targeting ligand, however stability of the peptide in human serum was unknown. Herein, we report the molecular modelling and design of an optimised peptide sequence based on interactions of RDP with the α7 subunit of the nicotinic acetylcholine receptor (nAChR). The new sequence, named DAS, designed around a 5-mer sequence which demonstrated optimal nAChR binding in silico, showed greatly improved stability for up to 8 hours in human serum in comparison to RDP, which degraded within 2 hours at 37 °C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1567737DOI Listing
January 2019
2 Reads

ANGPTL3: a novel biomarker and promising therapeutic target.

J Drug Target 2019 Jan 7:1-9. Epub 2019 Jan 7.

a School of Pharmacy , Hunan University of Chinese Medicine , Changsha , Hunan , China.

Angiopoietin-like protein 3 (ANGPTL3) belongs to a multifunctional secreted protein that mainly expresses in the liver, and is regulated by numerous post-translational modifications, including multiple cleavage and glycosylation. Accumulating evidences have revealed that ANGPTL3 plays a critical role in both biological processes, such as lipid metabolism, angiogenesis and haematopoietic function and pathological changes, including atherosclerosis, carcinogenesis, nephrotic syndrome, diabetes, liver diseases and so on. Thus, ANGPTL3 may serve as a potential biomarker in these diseases. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2019.1566342DOI Listing
January 2019
6 Reads

Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor.

J Drug Target 2019 Jan 7:1-14. Epub 2019 Jan 7.

a Department of Molecular Medicine, and Nanomedicine Unit , College of Medicine and Medical Sciences, Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Arabian Gulf University , Manama , Kingdom of Bahrain.

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that differs in progression, recurrence, and prognosis from other forms of breast cancer. The heterogeneity of TNBC has remained a challenge as no targeted therapy is currently available. Previously, we and others have demonstrated that raloxifene, a selective oestrogen receptor modulator, was also acting independently of the oestrogen receptor-α. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1566341DOI Listing
January 2019
2 Reads

Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours.

J Drug Target 2019 Jan 7:1-9. Epub 2019 Jan 7.

b The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora , CO , USA.

Targeting of nanoparticles to tumours can potentially improve the specificity of imaging and treatments. We have developed a multicompartmental pharmacokinetic model in order to analyse some of the factors that control efficiency of targeting to intravascular (endothelium) and extravascular (tumour cells and stroma) compartments. We make the assumption that transport across tumour endothelium is an important step for subsequent nanoparticle accumulation in the tumour (area-under-the-curve, AUC) regardless of entry route (interendothelial and transendothelial routes) and study this through a multicompartmental simulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2019.1566339DOI Listing
January 2019
1 Read

Engineering polymeric nanocapsules for an efficient drainage and biodistribution in the lymphatic system.

J Drug Target 2019 Jan 2:1-52. Epub 2019 Jan 2.

a Center for Research in Molecular Medicine & Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), School of Pharmacy, Universidade de Santiago de Compostela , Campus Vida , 15706 Santiago de Compostela , Spain.

Polymer-based nanocarriers have shown potential for enhancing the immunological response of antigens. However, the key drivers for this response have not been fully elucidated. The objective of this work was to evaluate the influence of particle size (≈100 vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1561886DOI Listing
January 2019
2 Reads

NLRP3 inflammasome contributes to neurovascular unit damage in stroke.

J Drug Target 2019 Jan 2:1-22. Epub 2019 Jan 2.

a Department of Neurology , China-Japan Union Hospital of Jilin University , No. 126 Xiantai Street , Changchun 130000 , Jilin , China.

Recently, a wealth of information has emerged connecting the activation of the NLRP3 (NOD-like receptor family pyrin domain-containing 3) inflammasome to stroke pathogenesis, although the exact influence of the NLRP3 inflammasome on stroke is still in the stage of preliminary study and is awaiting further confirmation. In this paper, we will review the structure, assembly and activation of the NLRP3 inflammasome and its expression in the neurovascular units and will speculate on its possible roles in neurovascular injury post-stroke. Evidence on this topic suggests that targeting NLRP3-mediated inflammation at multiple levels may provide a new therapeutic strategy to prevent the deterioration of neurovascular units after stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1564925DOI Listing
January 2019
1 Read

Characteristics and mechanism associated with drug conjugated inorganic nanoparticles.

J Drug Target 2019 Jan 2:1-65. Epub 2019 Jan 2.

a Centre of Advanced Study in Physics, Department of Physics, Panjab University , Chandigarh - 160014 , India.

Nanoparticles have several exciting applications nowadays almost in every area. Biomedical field is one of them where nanoparticles show potential for various applications due to their exceptional and exciting properties. The presence of heavy metals in inorganic nanoparticles lead to toxicity in the biological system, therefore, their direct use for drug delivery is restricted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1561888DOI Listing
January 2019
1 Read

Anticancer activity of polyphyllin I in nasopharyngeal carcinoma by modulation of lncRNA ROR and P53 signalling.

J Drug Target 2019 Jan 2:1-6. Epub 2019 Jan 2.

d Department of Oncology , Zhejiang Hospital , Hangzhou , PR China.

Nasopharyngeal carcinoma (NPC) is the most common aggressive squamous cell carcinoma in head and neck cancers. Although advanced radiochemotherapy has been applied, the prognosis of NPC patients still remains poor due to the regional relapse and distant metastasis. Polyphyllin I (PP I) is extracted from natural herb Paris polyphylla that has been widely used in cancer treatment and long non-coding RNA (lncRNA) has been reported to play a key role in the anti-tumour activity of PP I. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1561887DOI Listing
January 2019
1 Read

Chitosan-based nanotherapeutics for ovarian cancer treatment.

J Drug Target 2018 Dec 31:1-14. Epub 2018 Dec 31.

a Department of Medical Biotechnology, Faculty of Advanced Medical Sciences , Tabriz University of Medical Sciences , Tabriz , Iran.

Chitosan is one of the low toxic and natural polysaccharides which is obtained from deacetylation of chitin. Chitosan-based nanoparticles have good biodegradation and bio-distribution in the biological milieu, which have made it as one of the most attractive nanocarriers for delivering different therapeutic agents to the tumour cells especially ovarian cancer cell lines. Chitosan can covalently and non-covalently be modified and attached to different polymers and targeting moieties through its free amine groups and reach to the tumour site through passive and active targeting strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1564923DOI Listing
December 2018
2 Reads

Potential use of aptamers for diagnosis and treatment of pancreatic cancer.

J Drug Target 2018 Dec 31:1-13. Epub 2018 Dec 31.

c Department of Chemistry , Waterloo Institute for Nanotechnology, University of Waterloo , Waterloo , Canada.

Pancreatic cancer (PC) is highly malignant with a low 5-year survival rate. PC currently does not have good early diagnostic markers and responses poorly to chemotherapeutic drugs. The search for better biomarkers and developing more effective chemotherapy are important ways to improve the healthcare of PC patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1564924DOI Listing
December 2018
9 Reads

Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy.

J Drug Target 2018 Dec 27:1-10. Epub 2018 Dec 27.

a Department of Pharmaceutics, School of Pharmacy , Ningxia Medical University , Yinchuan , People's Republic of China.

Liposomes are versatile delivery systems and immunological adjuvants that not only can load various antigens, such as proteins, peptides, nucleic acids and carbohydrates, but also can combine them with immunostimulators. Liposomes have great potential in the development of new types of vaccines, and much effort has been devoted to enhancing vaccine efficacy in recent years. Different types of immune cells such as macrophages and dendritic cells play an important role in the immune response and in preventing or treating cancer, allergy or many other infectious diseases. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1547734DOI Listing
December 2018
7 Reads

Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight.

J Drug Target 2018 Dec 24:1-9. Epub 2018 Dec 24.

a College of Pharmacy , Qatar University , Doha , Qatar.

Triple negative breast cancers (TNBCs) are aggressive heterogeneous cancers with not yet determined conventional targeted medication. Therefore, identification of new alternatives or improved treatment options to combat this deadly disease is highly needed. On the other hand, various derived products with chalcone scaffold were historically considered excellent candidates for the development of anticancer drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1561889DOI Listing
December 2018
2 Reads

Nano-carriers for drug routing - Towards a new era.

J Drug Target 2018 Dec 20:1-66. Epub 2018 Dec 20.

b Integrated CMC External Innovation - Sanofi R&D - 82, avenue Raspail , 94250 Gentilly.

The objective of this article is to propose a re-visiting of the paradigms of nano-carriers based drug routing from an industrial viewpoint. The accumulation of drugs in specific body compartments after intravenous administration and the improvement of the oral bioavailability of peptides were taken as examples to propose an update of the translational framework preceding industrialization. In addition to the recent advances on the biopharmacy of nano-carriers, the evolution of adjacent disciplines such as the biology of diseases, the chemistry of polymers, lipids and conjugates, the physico-chemistry of colloids and the assembling of materials at the nanoscale (referred to as microfluidics) are taken into account to consider new avenues in the applications of drug nano-carriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1561891DOI Listing
December 2018
3 Reads

Poly(ethylene glycol)-alendronate coated nanoparticles for magnetic resonance imaging of lymph nodes.

J Drug Target 2018 Dec 4:1-11. Epub 2018 Dec 4.

a Department of Chemistry and Applied Biosciences , Institute of Pharmaceutical Sciences, ETH Zurich , Zurich , Switzerland.

Nanoparticulate systems can passively target regional lymphatic vessels and lymph nodes (LNs) after interstitial administration. Highly sensitive non-invasive imaging techniques, such as magnetic resonance imaging (MRI), can take advantage from particles' lymphotropic properties to provide a reliable tool to monitor lymphatic function and LN morphology with high spatial resolution. In this work, we developed and characterised a bioerodible nanosystem with MRI contrast properties, based on poly(ethylene glycol)-alendronate stabilised gadolinium calcium phosphate nanoparticles (NPs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1545235DOI Listing
December 2018
10 Reads

Precise tuning of disulfide crosslinking in mRNA polyplex micelles for optimizing extracellular and intracellular nuclease tolerability.

J Drug Target 2018 Nov 30:1-39. Epub 2018 Nov 30.

a Innovation Center of NanoMedicine (iCONM) , Kawasaki Institute of Industrial Promotion , Kawasaki , Kanagawa 210-0821 , Japan.

The major issues in messenger (m)RNA delivery are rapid mRNA degradation in the extracellular and intracellular spaces, which decreases the efficiency and duration for protein expression from mRNA. Stabilization of mRNA carriers using environment-responsive crosslinkings has promises to overcome these issues. Herein, we fine-tuned the structure of disulfide crosslinkings, which are selectively cleaved in the intracellular reductive environment, using the mRNA-loaded polyplex micelles (PMs) prepared from poly(ethylene glycol)-poly(L-lysine) (PEG-PLys) block copolymers, particularly by focusing on cationic charge density after the crosslinking. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1550646DOI Listing
November 2018
3 Reads

HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers.

J Drug Target 2018 Nov 27:1-30. Epub 2018 Nov 27.

a Department of General Surgery , Xiangya Hospital of Central South University , Changsha , Hunan , China , 410008.

Pancreatic cancer is one of the deadliest cancers across the world with an average 5-year survival rate of less than <6%. In this study, gemcitabine (GEM) and HIF1α-siRNA loaded GE-11 peptide conjugated liposome was successfully prepared and evaluated for its antitumor efficacy in pancreatic cancer cells. The GE11 increased the targeting specificity of liposome carrier and increased the intracellular concentrations in the cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1552276DOI Listing
November 2018
1 Read

The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: Implications for targeting tumor-initiating cells.

J Drug Target 2018 Nov 26:1-43. Epub 2018 Nov 26.

a Center for Pharmaceutical Biotechnology and Nanomedicine, Department of Pharmaceutical Sciences , Northeastern University Boston MA 02115.

Glioblastomas (GBMs) are known to harbor subsets of cells known as tumor-initiating cells (TICs), which are responsible for the maintenance, invasiveness and recurrence of GBMs. Conventional chemotherapeutics act on rapidly dividing cells, sparing the TICs and result in tumor relapse. Resveratrol, (RES) has shown chemopreventive effects in all the major stages of cancer including initiation, promotion and progression, but poor physico-chemical and pharmacokinetic properties limit its use as a free drug. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1550647DOI Listing
November 2018
4 Reads

Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug.

J Drug Target 2018 Nov 23:1-11. Epub 2018 Nov 23.

a The Institute for Drug Research of the School of Pharmacy , The Hebrew University of Jerusalem , Jerusalem , Israel.

Lopinavir (LPV), an efficient drug for HIV infection treatment, was incorporated into biodegradable PLGA nanocapsules (NCs) embedded in microparticles (MCPs) using the spray-drying technique in an attempt to bypass the P-gp efflux and protect the drug from CYP3A pre-systemic metabolism without ritonavir (RTV). SEM observations confirmed the formation of NCs and their entrapment in the MCPs. LPV-loaded NCs and free LPV were released from the MCPs at pH of 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1552275DOI Listing
November 2018
3 Reads

Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules.

J Drug Target 2018 Nov 21:1-12. Epub 2018 Nov 21.

a Laboratoire d'Automatique et de Génie des Procédés (LAGEP) , Univ Lyon, Université Claude Bernard Lyon 1 , Villeurbanne , France.

In this work, a novel lipophilic 5-fluorouracil (5-FU) derivative was synthesised and encapsulated into lipid nanocapsules (LNC). 5-FU was modified with lauric acid to give a lipophilic mono-lauroyl-derivative (5-FU-C12, MW of about 342 g/mol, yield of reaction 70%). 5-FU-C12 obtained was efficiently encapsulated into LNC (encapsulation efficiency above 90%) without altering the physico-chemical characteristics of LNC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1547733DOI Listing
November 2018
19 Reads

LOX/LOXL in pulmonary fibrosis: potential therapeutic targets.

J Drug Target 2018 Nov 20:1-7. Epub 2018 Nov 20.

b Department of Biochemistry , Boston University School of Medicine , Boston , MA , USA.

Lysyl oxidase (LOX) and lysyl oxidase-like proteins (LOXL), a family of extracellular matrix (ECM) crosslinking enzymes that have been recognised as playing an important role in fibrogenesis for more than 40 years, are logical targets for antifibrotic treatments. Pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), is a progressive and lethal disease characterised by excessive deposition of ECM in the lung parenchyma. In this review, we discuss the current clinical approaches for IPF and review members of LOX family-LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in IPF patients and in animal models of bleomycin-induced pulmonary fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1550649DOI Listing
November 2018
3 Reads

Transport and Delivery of Interferon-α Through Epithelial Tight Junctions via pH-Responsive Poly(Methacrylic Acid Grafted Ethylene Glycol) Nanoparticles.

J Drug Target 2018 Nov 20:1-33. Epub 2018 Nov 20.

b McKetta Department of Chemical Engineering , The University of Texas at Austin , Austin , TX 78712 , USA.

Whereas significant advancements have been made in our fundamental understanding of cancer, they have not yet translated into effective clinical cancer treatments. One of the areas that has the potential to improve the efficacy of cancer therapies is the development of novel drug delivery technologies. In particular, the design of pH-sensitive polymeric complexation hydrogels may allow for targeted oral delivery of a wide variety of chemotherapeutic drugs and proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1547732DOI Listing
November 2018
12 Reads

PDK2 induces Cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.

J Drug Target 2018 Nov 20:1-11. Epub 2018 Nov 20.

a The First Affiliated Hospital of Xi'an Jiaotong University - Department of Respiratory and Critical Care Medicine . Xi'an, Shaanxi . China .

Recurrence of lung adenocarcinoma has become one of the most frequent causes of major cancer incidence and mortality worldwide according to its frequently gained resistance to chemotherapies. In this study, we identified a poorly-studied kinase pyruvate dehydrogenase kinase isoform 2 (PDK2) as the most up-regulated kinase encoding gene in Cisplatin resistant lung adenocarcinoma. Additionally, PDK2-dependent Cisplatin-resistance promotes tumor growth of lung adenocarcinoma both in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1550648DOI Listing
November 2018
17 Reads

A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC.

J Drug Target 2018 Nov 1:1-9. Epub 2018 Nov 1.

a State Key Laboratory of Bioactive Substances and Functions of Natural Medicines , Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China.

NSCLC is a worldwide challenge due to its high incidence and poor survival. PI3K-Akt-mTOR (PAM) pathway is one of the major pathways that mediate receptor tyrosine kinases (RTKs) signalling transduction. Aberration in PAM pathway is indicated correlating with poor prognosis of NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1542533DOI Listing
November 2018
4 Reads

Heme metabolism as a therapeutic target against protozoan parasites.

J Drug Target 2018 Oct 31:1-13. Epub 2018 Oct 31.

a Laboratório de Interação celular e molecular, Departamento de Biologia Celular e Molecular , Universidade Federal Fluminense, Rua Outeiro São João Batista , Rio de Janeiro , Brazil.

Neglected tropical diseases caused by protozoan parasites affect the life of millions of people worldwide, causing mortality, morbidity and high economic and social burden. The search for new drug targets and therapeutic strategies to fight these pathogens are necessary, since many current drugs have limited effects, cause severe side effects and their use has resulted in pathogen resistance. Heme (iron protoporphyrin IX) is a ubiquitous molecule important in many biological processes, including the homeostasis, growth and development of human pathogens such as trypanosomatids (Trypanosoma cruzi, Trypanosoma brucei and Leishmania spp. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1536982DOI Listing
October 2018
11 Reads

GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models.

J Drug Target 2018 Oct 30:1-9. Epub 2018 Oct 30.

b International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy , Jinan University , Guangzhou , China.

Collective data suggest tropomyosin-related kinase B (TrkB), which is correlated with the growth, migration and poor prognosis of neuroblastoma (NB), is a potential target for NB target therapy. Several Phase I/II pan-Trk inhibitors display impressive clinical outcomes but still no drug has been approved for general use. In this paper, we report a novel structural TrkB inhibitor GZD2202, a structural derivative of our previously identified DDR1 antagonists. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1533964DOI Listing
October 2018
4 Reads

Targeting central nervous system pathologies with nanomedicines.

J Drug Target 2018 Oct 18:1-13. Epub 2018 Oct 18.

a Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology , George S. Wise Faculty of Life Sciences, Tel Aviv University , Tel Aviv , Israel.

One of the major challenges in drug development is the delivery of therapeutics to the central nervous system (CNS). The blood-brain barrier (BBB), which modulates the passage of molecules from the CNS, presents a formidable obstacle that limits brain uptake of therapeutics and, therefore, impedes the treatment of multiple neurological pathologies. Targeted nanocarriers present an excellent opportunity for drug delivery into the brain leveraging on endogenous receptors to transport therapeutics across the BBB endothelium. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1533556DOI Listing
October 2018
2 Reads

NRG1 PLGA MP locally induce macrophage polarisation toward a regenerative phenotype in the heart after acute myocardial infarction.

J Drug Target 2018 Oct 17:1-9. Epub 2018 Oct 17.

a Pharmacy and Pharmaceutical Technology Department , School of Pharmacy, Universidad de Navarra , Pamplona , Spain.

Neuregulin-1 loaded poly(lactic-co-glycolic acid) (PLGA) microparticles hold great promise for treating acute myocardial infarction, as they have been proved to recover heart function and induce positive heart remodelling in preclinical studies. More recently, the inflammatory response of the heart after acute myocardial infarction (AMI) has been identified as one of the major mechanisms in cardiac tissue remodelling and repair. However, the connection between neuregulin-1 PLGA microparticles and inflammation is still not well characterised. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1531417DOI Listing
October 2018
2 Reads

Phage-displayed peptides targeting specific tissues and organs.

J Drug Target 2018 Oct 24:1-11. Epub 2018 Oct 24.

a Department of Biotechnology and Biosciences , University of Milano-Bicocca , Milan , Italy.

Phage display is a powerful and widely used technique to find novel peptide ligands. A massive amount of peptide sequences have been identified for all kinds of materials, and peptides that may have targeting capabilities towards specific cells and tissues have received special attention in biomedical sciences. As a result, it is increasingly harder to follow all the work that has been done, which sometimes leads to many promising ligands receiving little attention, together with the publication of false positives that have already been found. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1531419DOI Listing
October 2018
1 Read

Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles.

J Drug Target 2018 Oct 18:1-8. Epub 2018 Oct 18.

a Department of Biotechnology , Sri Jayachamarajendra College of Engineering, JSS Science and Technology University , Mysuru , India.

The present research work describes the use of photodynamic therapy (PDT) of drug 5-aminolevulinic acid (5-ALA) conjugated with microbial synthesised silver nanoparticles on skin melanoma (B16F10) and epidermoid carcinoma (A431) cell lines. Silver nanoparticles were synthesised using the bacterial strain Bacillus licheniformis. The morphology of the nanoparticles was studied using scanning electron microscopy (SEM) and elemental analysis of nanoparticles was carried out using energy dispersive X-ray spectroscopy (EDX). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1531418DOI Listing
October 2018
3 Reads

Major effects on blood-retina barrier passage by minor alterations in design of polybutylcyanoacrylate nanoparticles.

J Drug Target 2018 Nov 26:1-9. Epub 2018 Nov 26.

a Institute of Medical Psychology, Otto-von-Guericke University , Magdeburg , Germany.

Because the blood-brain barrier (BBB) is an obstacle for drug-delivery, carrier systems such as polybutylcyanoacrylate (PBCA) nanoparticles (NPs) have been studied. Yet, little is known of how physiochemical features such as size, surfactants and surface charge influence BBB passage in vivo. We now used a rat model of in vivo imaging of the retina - which is brain tissue and can reflect the situation at the BBB - to study how size and surface charge determine NPs' ability to cross the blood-retina barrier (BRB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1531416DOI Listing
November 2018
1 Read

Application of titanium dioxide (TiO) nanoparticles in cancer therapies.

J Drug Target 2018 Oct 15:1-5. Epub 2018 Oct 15.

a Ege Universitesi Tip Fakultesi , Izmir , Turkey.

Cancer is one of the most common diseases all over the world; many people suffer from diverse types of cancer. However, currently there is no exact cure or therapy developed for cancer. On the other hand, nanoparticles are defined as microscopic particles that have dimensions less than 100 nm and they are known for their usage in health sciences and medicine, however a few harmful effects on different animal cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1527338DOI Listing
October 2018
1 Read

Liposome: composition, characterisation, preparation, and recent innovation in clinical applications.

J Drug Target 2018 Oct 15:1-20. Epub 2018 Oct 15.

a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China.

In the last decades, pharmaceutical interested researches aimed to develop novel and innovative drug delivery techniques in the medical and pharmaceutical fields. Recently, phospholipid vesicles (Liposomes) are the most known versatile assemblies in the drug delivery systems. The discovery of liposomes arises from self-forming enclosed phospholipid bilayer upon coming in contact with the aqueous solution. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1527337DOI Listing
October 2018
32 Reads

siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.

J Drug Target 2019 Feb 11:1-13. Epub 2019 Feb 11.

a Jeffrey Cheah School of Medicine and Health Sciences , Monash University Malaysia , Bandar Sunway, Subang Jaya , Malaysia.

Chemotherapy, the commonly favoured approach to treat cancer is frequently associated with treatment failure and recurrence of disease as a result of development of multidrug resistance (MDR) with concomitant over-expression of drug efflux proteins on cancer cells. One of the most widely used drugs, doxorubicin (Dox) is a substrate of three different ATP-binding cassette (ABC) transporters, namely, ABCB1, ABCG2 and ABCC1, predominantly contributing to MDR phenotype in cancer. To silence these transporter-coding genes and thus enhance the therapeutic efficacy of Dox, pH-sensitive carbonate apatite (CA) nanoparticles (NPs) were employed as a carrier system to co-deliver siRNAs against these genes and Dox in breast cancer cells and in a syngeneic breast cancer mouse model. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1525388DOI Listing
February 2019
6 Reads

An Overview on the Methods of Determining the Activity of Indoleamine 2, 3-dioxygenase 1.

J Drug Target 2018 Sep 14:1-14. Epub 2018 Sep 14.

a Collaborative Innovation Center of New Drug Research and Safety , Henan Province , China.

Immune escape plays an important hallmark of cancer. The tryptophan-catabolizing enzyme indoleamine 2, 3-dioxygenase 1 (IDO1) is involved in the immune escape mechanism of human tumors, the expression of which is associated with a poor prognosis in cancer and correlated with tumor progression clinically. Therefore, finding the inhibitors targeting IDO1 may be an impellent approach that can reverse the complicated processes in tumor immune escape and induce an antitumor response as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1523416DOI Listing
September 2018
6 Reads

Alive attenuated Salmonella as a cargo shuttle for smart carrying of gold nanoparticles to tumour hypoxic regions.

J Drug Target 2018 Oct 3:1-10. Epub 2018 Oct 3.

d Department of Chemistry , University of Isfahan , Isfahan , Iran.

In the present study, alive attenuated Salmonella typhi Ty21a was introduced as a vehicle for smart delivery of gold nanoparticles to the tumours' hypoxic regions. At the first step, the uptakes of gold nanoparticles with seven different decorations by S. typhi Ty21a was investigated using flow cytometry and inductively coupled plasma optical emission spectroscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2018.1523417DOI Listing
October 2018
5 Reads

The roles and mechanisms of G3BP1 in tumour promotion.

J Drug Target 2018 Oct 3:1-6. Epub 2018 Oct 3.

a NHC Key Laboratory of Biotechnology of Antibiotics , Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences , Beijing , China.

Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) is a SH3 domain-binding protein that is overexpressed in a variety of tumour tissues and cancers, such as head and neck cancer, lung cancer, prostate cancer, colon cancer and breast cancer. G3BP1 promotes tumour cell proliferation and metastasis and inhibits apoptosis by regulating the Ras, TGF-β/Smad, Src/FAK and p53 signalling pathways. At present, polypeptides targeting G3BP1 have shown anti-tumour activity and G3BP1 also involved in anti-cancer effects of some polyphenolic compounds (resveratrol and EGCG). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1523415DOI Listing
October 2018
14 Reads

Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics.

J Drug Target 2018 Oct 3:1-10. Epub 2018 Oct 3.

b Departamento de Química, Centro de Ciências da Natureza , Universidade Federal do Piauí, Campus Universitário Ministro Petrônio Portella, Ininga , Teresina , Brazil.

The use of nanoparticulate systems with action in breast and ovarian cancer has been highlighted in recent years as an alternative to increasing the therapeutic index of conventional anticancer drugs. Thus, nanoparticles have advantageous characteristics in the treatment of cancer. Several nanocarriers of drugs and nanoparticles are described in the literature. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1061186X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1061186X.2018.1523418DOI Listing
October 2018
13 Reads